Compare · AZTR vs NVO
AZTR vs NVO
Side-by-side comparison of Azitra Inc (AZTR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZTR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 105593.7x AZTR ($2.0M).
- Over the past year, AZTR is down 90.7% and NVO is down 29.3% - NVO leads by 61.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for AZTR).
- NVO has more recent analyst coverage (25 ratings vs 0 for AZTR).
- Company
- Azitra Inc
- Novo Nordisk A/S
- Price
- $0.13+0.24%
- $48.78+1.22%
- Market cap
- $2.0M
- $215.95B
- 1M return
- -38.68%
- +2.89%
- 1Y return
- -90.69%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2023
- News (4w)
- 3
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AZTR
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- /C O R R E C T I O N -- Azitra, Inc./
- Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
- SEC Form SCHEDULE 13G filed by Azitra Inc
- President and CEO Salva Francisco D. converted options into 4,064,050 shares, increasing direct ownership by 18,273% to 4,086,291 units (SEC Form 4)
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
- Azitra, Inc. to Present at 2026 BIO International Convention
- Azitra Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Azitra Inc
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S